Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism PORCN inhibitors(Protein-serine O-palmitoleoyltransferase porcupine inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H17N7O3 |
InChIKeyQTRXIFVSTWXRJJ-UHFFFAOYSA-N |
CAS Registry1638250-96-0 |
Start Date30 Nov 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2015 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 1 | SG | 30 Nov 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 Oct 2015 | |
Advanced Malignant Solid Neoplasm | Phase 1 | SG | 01 Oct 2015 | |
Neoplasms | Phase 1 | - | - | |
Neoplasms | Phase 1 | - | - | |
Neoplasms | Phase 1 | - | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 20 | (jsmgpmzdkf) = caiiucapoa reahrsaxti (zgdwpdnqno ) View more | Positive | 26 May 2023 | |||
Phase 1 | 8 | (raosrssviz) = 25% kwnddtivvw (bouwkqzgij ) View more | - | 24 Nov 2018 | |||
Denosumab | |||||||
Phase 1 | 16 | (sdlsueyujt) = wieghxlxcr dsmiqlixiw (bzbjiuwuec ) View more | - | 30 May 2017 |